BORJE S ANDERSSON to Leukemia, Myeloid
This is a "connection" page, showing publications BORJE S ANDERSSON has written about Leukemia, Myeloid.
Connection Strength
1.132
-
5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010 Mar; 34(3):364-72.
Score: 0.240
-
Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res. 2008 Nov; 32(11):1684-97.
Score: 0.217
-
Model studies of cyclophosphamide resistance in human myeloid leukemia. Cancer Treat Res. 2002; 112:211-35.
Score: 0.141
-
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia. 1995 Dec; 9(12):2100-8.
Score: 0.092
-
Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant. 2011 Jun; 17(6):923-9.
Score: 0.065
-
Suitability of a new stable acetal analogue of aldoifosphamide for purging leukemic cells from human bone marrow. Leukemia. 1990 Jun; 4(6):435-40.
Score: 0.063
-
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64.
Score: 0.053
-
Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet Cytogenet. 1987 Feb; 24(2):335-43.
Score: 0.050
-
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007 Jan; 13(1):56-64.
Score: 0.050
-
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9.
Score: 0.036
-
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.
Score: 0.026
-
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993 Sep 09; 329(11):757-61.
Score: 0.020
-
Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer. 1988 Sep 15; 62(6):1171-8.
Score: 0.014
-
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988 Aug 15; 62(4):672-6.
Score: 0.014
-
Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987 Aug; 27(2):349-56.
Score: 0.013
-
Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines. Blood. 1987 Mar; 69(3):721-6.
Score: 0.013
-
Analysis of nuclear m-AMSA content by DNA fluorochrome competition. Eur J Cancer Clin Oncol. 1986 Jul; 22(7):883-9.
Score: 0.012
-
The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia. Leuk Res. 1986; 10(12):1401-9.
Score: 0.012
-
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104.
Score: 0.003